Cancers often acquire loss-of-function mutations in tumor suppressor genes, leading to reduced or absent protein products. This creates a challenge for targeted therapies, as there are no cancer-specific proteins for drugs to bind. To address this, GRETTA, a computational tool, has been developed to map genetic networks of cancer-associated genes and predict targetable vulnerabilities (i.e., synthetic lethalities) in cancer cells with specific somatic mutations. The goal is to evaluate how GRETTA can inform and enhance precision cancer medicine.
Gretta
Canada’s Michael Smith Genome Sciences Centre respectfully acknowledges that we operate on the traditional, ancestral and unceded territories of the xʷməθkwəy̓əm (Musqueam), Səl̓ílwətaʔ/Selilwitulh (Tsleil-Waututh), and Skwxwú7mesh (Squamish) nations who have cared and nurtured this land for all time. We give thanks, as uninvited guests, to be able to live and work on these lands.
